The first reaction of ceramide glycosylation in sphingolipid metabolism is catalyzed by glucosylceramide synthase (GCS), which changes ceramide into glucosylceramide. By regulating ceramide and glycosphingolipids (GSLs), this glycosylation by GCS is a crucial step in controlling the modulation of cellular activities.Ceramide levels rise in response to stresses like chemotherapy, which causes cells to enter apoptosis or autophagy. Ceramide glycosylation, however, quickly removes ceramide and, as a result, these induced processes, protecting cancer cells. Additionally, persistently increased ceramide glycosylation can raise GSLs and contribute to the selection of drug-resistant cancer cells. In numerous drug-resistant cancer cells as well as breast, colon, and leukemia tumors that exhibit a poor response to chemotherapy, GCS is overexpressed. Inhibition of GCS makes cancer cells more susceptible to anticancer medications and kills cancer stem cells because ceramide glycosylation by GCS is a rate-limiting step in GSL synthesis.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V121911 | (R)-cGAS-IN-4 | 2987886-48-4 | (R)-cGAS-IN-4 is the R-enantiomer of cGAS-IN-4. |
|
V83504 | (−)-L-threo-PDMP hydrochloride | 161491-04-9 | |
|
V130935 | CAIF | CAIF is an irreversible, selective allosteric covalent inhibitor that inhibits fucosyltransferase 8 (FUT8) with an IC50 value of 5.7 μM. | |
|
V70294 | D-threo-PDMP | 109836-82-0 | D-threo-PDMP is a potent inhibitor of glucosylceramide synthase (GCS), which can reduce cell surface glycosphingolipids by inhibiting glycosylation, reducing the total length of axonal plexuses and the number of axonal branch points. |
|
V70297 | D-threo-PPMP | 139889-53-5 | D-threo-PPMP is a potent inhibitor of glucosylceramide (GlcCer) synthase. |
|
V70295 | D-threo-PPMP hydrochloride | 139889-65-9 | D-threo-PPMP HCl is a potent inhibitor of glucosylceramide (GlcCer) synthase. |
|
V83502 | DL-threo-PDMP hydrochloride | 80938-69-8 | |
|
V116177 | EXEL-0346 | 1239893-96-9 | EXEL-0346 is an orally effective glucosylceramide synthase (GCS) inhibitor with an IC50 of 2 nM. |
|
V87805 | Fucosyltransferase 8 | Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyltransferase that catalyzes the transfer of focal residues from GDP-fucose to the innermost N-acetylglucosamine residues of N-glycans. | |
|
V79532 | Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) | Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyltransferase that catalyzes the transfer of focused residues from GDP-fucose to the innermost N-acetylglucosamine residues of N-glycans. | |
|
V105127 | FUT8-IN-1 | FUT8-IN-1 (Compound 37) is an inhibitor of α-1,6-fucosyltransferase (FUT8) with KD of 49 nM and IC50 of approximately 50 µM. | |
|
V85161 | Glucosylceramide synthase-IN-4 | 2776965-41-2 | |
|
V136736 | Glucosylceramide synthase-IN-5 | 3118501-69-9 | Glucosylceramide synthase-IN-5 is a glucosylceramide synthase (GCS) inhibitor that can be used to study diseases and disorders related to GCS activity, such as lysosomal storage disorders. |
|
V136737 | Glucosylceramide synthase-IN-6 | 3118501-71-3 | Glucosylceramide synthase-IN-6 is a glucosylceramide synthase (GCS) inhibitor that can be used to study diseases and disorders related to GCS activity, such as lysosomal storage disorders. |
|
V94320 | Ibiglustat hydrochloride | 1629063-79-1 | Ibiglut hydrochloride is an orally active, blood-brain-permeable glucosylceramide synthase (GCS) inhibitor. |
|
V70296 | Ibiglustat succinate (Venglustat succinate; SAR402671 succinate; GZ402671 succinate) | 1629063-80-4 | Ibiglustat (Venglustat) succinate is an orally bioactive, BBB (blood-brain barrier) permeable (penetrable) glucosylceramide synthase (GCS) inhibitor. |
|
V87807 | UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase 2 | UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase 2 (EC:2.4.1.313; B3GALNT2; β-1,3-N-acetylgalactosaminyltransferase II) is a glycosyltransferase. | |
|
V81662 | UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase 2 (EC:2.4.1.313; B3GALNT2; β-1,3-N-acetylgalactosaminyltransferase II) | UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase 2 (EC:2.4.1.313; B3GALNT2; β-1,3-N-acetylgalactosaminyltransferase II) is a glycosyltransferase. | |
|
V147190 | XL-3156 | 3117797-30-2 | XL-3156 is a cGAS inhibitor. |
|
V87806 | α-N-Acetylglucosaminidase | α-N-Acetylglucosaminidase (EC:3.2.1.50; NAGLU; UFHSD 1) is a glycosyltransferase. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
